PD-1 is a receptor which, through a variety of metabolic processes, leads to inactivation of T cells. In the therapy of the cancer, one of the promising new drugs is BMS-936 558, an antibody directed against PD-1 receptor. The effectiveness of the new therapy has been demonstrated in large randomized trials for renal cancer, non-small cell lung cancer and melanoma. Currently, the drug is in the second phase of clinical trials (treatment of renal cell carcinoma). The obtained results are very promising, however the effect of the antibody must be evaluated in the further studies.
Scientists from Cold Spring Harbor Laboratory (CSHL) have identified an enzyme, which is significant regulator of breast cancer development and metastasis. PTPN23 is intracellular protein, which plays key role in cell signaling and can promote metastases. Read full text »
Migraine is a problem that affects approximately 15% of adults. A splitting headache is often accompanied by a number of neurological and non-neurological manifestations. Patients affected by this ailment are put under a higher risk of developing such conditions as anxiety or depression. Migraine has an influence on the visuo-spatial memory and seriously affects selective attention tasks. This malady disables the proper function of the human body – it brings a headache of such a severe intensity that it may be aggravated by just a normal physical activity. Therefore migraine is a major problem for a working community. Read full text »